Kyverna Therapeutics, Inc. Finance Lease, Liability, Undiscounted Excess Amount
Kyverna Therapeutics, Inc. (KYTX) had Finance Lease, Liability, Undiscounted Excess Amount of $26.00 thousand as of 2026-03-31, per its 10-Q filed 2026-05-12.
Financial Statements › Notes › Leases
us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount · last filed 2026-05-12
- 2026-03-31: Finance Lease, Liability, Undiscounted Excess Amount $26.00K.
- 2025-12-31: Finance Lease, Liability, Undiscounted Excess Amount $12.00K.
- 2024-12-31: Finance Lease, Liability, Undiscounted Excess Amount $145.00K.
- 2024-09-30: Finance Lease, Liability, Undiscounted Excess Amount $172.00K.
| Period end | Finance Lease, Liability, Undiscounted Excess Amount |
|---|---|
| 2026-03-31 | $26.00K 10-Q · filed 2026-05-12 |
| 2025-12-31 | $12.00K 10-K · filed 2026-03-26 |
| 2024-12-31 | $145.00K 10-K · filed 2025-03-27 |
| 2024-09-30 | $172.00K 10-Q · filed 2024-11-13 |
| 2024-06-30 | $113.00K 10-Q · filed 2024-08-12 |
| 2024-03-31 | $152.00K 10-Q · filed 2024-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |